William Blair & Company
Tracked across 7 events · 106 articles · First seen Nov 19, 2025 · Last active May 28, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
Impact: William Blair & Company acted as the lead manager for Kailera Therapeutics's IPO, facilitating the offering and earning underwriting fees.
Apr 16, 2026 · 8 articles
Business
Impact: William Blair & Company is one of the 16 banks participating in smaller roles for the SpaceX IPO.
Mar 27, 2026 · 61 articles
Business
The biotech sector is experiencing a significant surge in mergers and acquisitions (M&A) in 2026, with deal values already reaching $84 billion in the first quarter, making it the strongest start since 2019. This accelerated…
Impact: William Blair & Company is an investment banking firm whose director, Eason Hahm, provided estimates on the revenue facing patent expirations in the biopharma sector.
May 01, 2026 · 6 articles
Business
Cellebrite announced its participation in a series of investor conferences scheduled for May and June 2026. Key executives, including Thomas E. Hogan (CEO), David Barnea (CFO), Roni Fialkov (SVP, Global Finance), and Andrew Kramer (VP,…
Impact: William Blair & Company is hosting one of the investor conferences where Cellebrite will participate, providing a platform for investor engagement.
May 08, 2026 · 7 articles
Business
Impact: William Blair acted as a placement agent in connection with the concurrent private placement financing.
Apr 14, 2026 · 7 articles
Business
Impact: William Blair & Company analysts provided commentary on the Adobe Inc.-Semrush deal, expressing positivity about Adobe restarting its M&A engine but noting the deal's limited impact on creative cloud business questions.
Nov 19, 2025 · 6 articles
NEWSDESK
Track William Blair & Company live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard